NK Cell ECM Receptor Editing for Enhanced Tumor Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer cells evade immune detection by downregulating Major Histocompatibility Complex Class I (MHC-I), rendering them resistant to CD8+ T cell elimination but vulnerable to Natural Killer (NK) cell killing, which is not effectively harnessed in current immunotherapies.
Innovation Solution
Modifying NK cells to increase, reduce, or eliminate expression of extracellular matrix (ECM) receptors using genetic engineering and chimeric antigen receptors (CARs) to enhance their cytotoxicity against cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NK cells are used to target MHC-I downregulated cancer cells, then cancer cell killing ability is improved, but NK cell cytotoxicity is inhibited by ECM receptors
Solution Approach 1:
The patent removes or reduces the expression of ECM receptors (such as CD49a, CD49b, CD51, CD55) on NK cells through genetic engineering approaches including CRISPR-Cas9 gene editing, RNA interference, or selective cloning. This extraction of inhibitory receptors eliminates their harmful effect on NK cell cytotoxicity while preserving the cells' ability to recognize and kill cancer cells that have downregulated MHC-I.
Solution Approach 2:
The patent modifies the expression levels of ECM receptors on NK cells by changing the genetic parameters of the cells. Through gene editing techniques, the expression of inhibitory ECM receptors is reduced or eliminated, fundamentally altering the functional parameters of NK cells to enhance their cytotoxic activity against tumor cells without compromising their target recognition capabilities.
2Reliability
If NK cells are genetically modified to enhance cytotoxicity, then anti-tumor efficacy is improved, but cell proliferation and expansion capability may be affected
Solution Approach 1:
The patent applies partial genetic modification by selectively targeting only specific ECM receptors (such as CD49a, CD49b, CD51, or CD55) for reduction or elimination, rather than进行全面 genetic改造. This partial action approach enhances anti-tumor efficacy by removing key inhibitory receptors while minimizing off-target effects on cell proliferation and expansion, thus maintaining productivity.
3Reliability
If ECM receptor expression is reduced on NK cells, then cytotoxicity is enhanced, but tissue homing and retention ability may be compromised
Solution Approach 1:
The patent applies local quality modification by selectively reducing or eliminating specific ECM receptors (such as CD49a, CD49b, CD51, CD55) that mediate inhibitory signals, while preserving other adhesion molecules and homing receptors that are essential for tissue localization. This selective approach enhances cytotoxicity at the local level of tumor interaction without compromising the overall tissue homing and retention capability of NK cells.
Data Source
AI summary
Provided herein are natural killer (NK) cells with increased, modified or deleted extracellular matrix (ECM) receptors, and methods of making and using the same for cancer immunotherapy, and treatment of chronic infections, inflammation, autoimmune diseases, or transplant rejection.